Exactech, Inc. (NASDAQ:EXAC) Director James G. Binch sold 747 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $28.40, for a total transaction of $21,214.80. Following the sale, the director now owns 3,554 shares in the company, valued at approximately $100,933.60. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Exactech, Inc. (NASDAQ EXAC) traded up 0.18% during trading on Tuesday, reaching $28.45. 17,383 shares of the company traded hands. The firm’s 50-day moving average is $29.94 and its 200-day moving average is $27.91. The stock has a market capitalization of $407.43 million, a PE ratio of 547.12 and a beta of 1.02. Exactech, Inc. has a 12-month low of $22.20 and a 12-month high of $31.90.

Exactech (NASDAQ:EXAC) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a net margin of 0.30% and a return on equity of 7.45%. Exactech’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.31 earnings per share. On average, equities analysts predict that Exactech, Inc. will post $1.29 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Exactech, Inc. (NASDAQ:EXAC) Director James G. Binch Sells 747 Shares” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/exactech-inc-nasdaqexac-director-james-g-binch-sells-747-shares.html.

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in Exactech by 11.3% in the fourth quarter. State Street Corp now owns 245,639 shares of the medical equipment provider’s stock worth $6,707,000 after buying an additional 25,011 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Exactech by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 751,750 shares of the medical equipment provider’s stock worth $20,523,000 after buying an additional 29,515 shares in the last quarter. Renaissance Technologies LLC boosted its position in Exactech by 7.2% in the fourth quarter. Renaissance Technologies LLC now owns 105,700 shares of the medical equipment provider’s stock worth $2,886,000 after buying an additional 7,100 shares in the last quarter. Foundry Partners LLC boosted its position in Exactech by 205.9% in the first quarter. Foundry Partners LLC now owns 155,436 shares of the medical equipment provider’s stock worth $3,917,000 after buying an additional 104,625 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in Exactech by 74.1% in the first quarter. Rice Hall James & Associates LLC now owns 99,270 shares of the medical equipment provider’s stock worth $2,502,000 after buying an additional 42,256 shares in the last quarter. 64.68% of the stock is owned by institutional investors and hedge funds.

Several analysts recently issued reports on the stock. Gabelli reiterated a “buy” rating on shares of Exactech in a research report on Monday, July 31st. BidaskClub lowered shares of Exactech from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Zacks Investment Research lowered shares of Exactech from a “hold” rating to a “sell” rating in a research report on Monday, April 10th. Finally, TheStreet raised shares of Exactech from a “c+” rating to a “b” rating in a research note on Tuesday, April 25th.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.